Healthcare and telemedicine stocks have delivered some of the market’s biggest winners in recent years, as investors bet on the growing demand for virtual care, wellness, and weight-loss solutions. Companies like Hims & Hers Health (HIMS) became investor favorites thanks to their aggressive expansion into telehealth and new treatment categories, including the booming GLP-1 weight-loss market.
However, the narrative took a sharp turn this week after CEO Andrew Dudum sold about $11 million worth of stock, sending shares tumbling more than 10%. The timing of the sale, amid regulatory worries and pricing pressure on GLP-1 generics, has raised eyebrows on Wall Street.
